A. Kohn

发表

A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.

C. McDougle, D. Posey, N. Swiezy, 2001, Journal of child and adolescent psychopharmacology.

Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.

C. McDougle, D. Posey, C. Erickson, 2009, Journal of child and adolescent psychopharmacology.

A prospective open-label study of aripiprazole in fragile X syndrome

C. McDougle, D. Posey, C. Erickson, 2011, Psychopharmacology.

Risperidone in children with autism and serious behavioral problems.

C. McDougle, D. Posey, F. Volkmar, 2002, The New England journal of medicine.

Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.

C. McDougle, D. Posey, F. Volkmar, 2005, The American journal of psychiatry.

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.

C. McDougle, D. Posey, J. McGough, 2005, Archives of general psychiatry.

Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.

C. McDougle, M. Davies, L. Scahill, 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.

C. McDougle, L. Ritz, L. Scahill, 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems.

C. McDougle, L. Ritz, L. Scahill, 2012, Journal of the American Academy of Child and Adolescent Psychiatry.

CONSCIENCE SENSITIVE PSYCHIATRIC DIAGNOSIS OF MALTREATED CHILDREN AND ADOLESCENTS

B. Stilwell, A. Kohn, M. Galvin, 2001 .